Abstract
Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is overexpressed in advanced stage prostate adenocarcinomas. As a novel target for in vivo prognostic and therapeutic approaches, the distribution pattern of PSMA in primary and metastatic tumors is of significant interest. In this study we addressed the cellular distribution and heterogeneity of PSMA expression. Paraffin-embedded sections of 51 patients with primary prostate carcinoma and distant metastases were evaluated. Immunohistochemistry was used to determine the cellular localization, staining intensity and positive cell fraction which were related to tumor type and growth pattern. We demonstrated differences in the intracellular localization of the PSMA immunostaining which seem to be related to the tumor differentiation pattern. A significant number of the primary tumors (7/51) and metastases (6/51) presented with highly heterogeneous PSMA expression and in further 2 primary, and 8 metastatic tumors the staining was in the negative range (<10% positive tumor cells). A direct correlation between histological parameters and PSMA expression could not be demonstrated. Our findings clearly support the feasibility but also direct to potential failures of PSMA-targeted in vivo diagnostic and therapeutic approaches in prostate cancer patients with distant metastasis.
Similar content being viewed by others
Abbreviations
- A:
-
Apical
- AB:
-
Antibody
- C:
-
Cytoplasmic
- GM:
-
Gabor Mehes
- IHC:
-
Immunohistochemistry
- M:
-
Membrane
- PSMA:
-
Prostate-Specific Membrane Antigen
- PSA:
-
Prostate Specific Antigen
- SD:
-
Standard Deviation
- SM:
-
Sebastian Mannweiler
- TUR:
-
Transurethrally Resected
References
Chang SS (2004) Overview of prostate-specific membrane antigen. Rev Urol 6:S13–S16
Pinto JT, Suffoletto BP, Berzin TM et al (1996) Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2:1445–1451
Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82:2256–2261
Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, Hautmann RE, Gschwendt JE, Kuefer R, Rubin MA (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38:696–701
Horoszewicz JS, Kawinski E, Murphy GP (1987) Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 7:927–936
Moreno JG, Croce CM, Fischer R et al (1992) Detection of hematogenous micrometastases in patients with prostate cancer. Cancer Res 52:6110–6112
Silver DA, Pellicer I, Fair WL et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissue. Clin Cancer Res 3:81–85
Chang S, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD Gaudin PB (1999) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5:2674–2681
Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326–334
Gleason DF (1977) Histologic grading and clinical staging of prostatic carcinoma. In: Tannebaum M (ed) Urologic pathology: the prostate. Lea & Febiger, Philadelphia, pp 171–197
Lopez-Beltran A, Mikuz G, Luque RJ, Mazzucchelli R, Montironi R (2006) Current practice of Gleason grading of prostate carcinoma. Virchows Arch 448(2):111–118
Douglas G. Altman: Practical Statistics for Medical Research Chapman & Hall/CRC 1 edition (November 22, 1990)
Bander NH (2006) Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 3(4):216–225
Sodee DB, Sodee AE, Bakale G (2007) Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med 37(1):17–28
Elsässer-Beile U, Wolf P, Gierschner D, Bühler P, Schultze-Seemann W, Wetterauer U (2006) A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 66(13):1359–1370
Ross JS, Sheehan CHE, Fisher HAG, Kaufman RP, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BVS (2003) Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 9:6357–6362
Zhigang Z, Wenly S (2004) Prostate stem cell antigen (PSCA) expression in human prostate cancer tissue and its potential role in prostate carcinogenesis and progression of prostate cancer. W J Surg Oncol 2:1–13
Bühler P, Wolf P, Gierschner D, Schabel I, Katzenwadel A, Schultze-Seemann W, Wetterauer U, Tacke M, Swamy M, Schamel WW, Elsässer-Beile U (2008) A bispecific diabody directed against prostate-specific membrane antigen and CD33 induces T-cell mediated lysis of prostate cancer cells. Can Immunol Immunother 57(1):43–52
Acknowledgments
The authors thank Elisabeth Patz and Anja Hausleitner for their excellent technical assistance and Harald Zöbl for the graphical layout and design.
Legal declaration
IRB approval formally obtained according to the votum 12-159 ex 01/02 at Medical University Graz, Austria.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mannweiler, S., Amersdorfer, P., Trajanoski, S. et al. Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis. Pathol. Oncol. Res. 15, 167–172 (2009). https://doi.org/10.1007/s12253-008-9104-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-008-9104-2